Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

Recruiting NCT07287137

Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study

Conditions: COVID -19, COVID - 19, COVID 19, Influenza, Respiratory Virus, Respiratory Viruses, Respiratory Virus Infection, Respiratory Virus Infections

Sex: All

Ages: 18 Years – 79 Years

Healthy volunteers: Yes

Phase: PHASE4

Enrollment: 54

Sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine

Location: Walter Reed National Military Medical Center Bethesda Maryland

Summary

CIRV2 is a Phase IV randomized, open-label, trial of FDA-approved COVID-19 and/or influenza vaccines (no more than minimal risk) with longitudinal follow-up. In 2026 CIRV2 will compare immunogenicity and reactogenicity of the recombinant Novavax COVID-19 vaccine and the mRNA Pfizer-BioNTech COVID-19 vaccine.

Eligibility Criteria

Inclusion Criteria 1. 18-79 years old 2. Have a history of any of the following risk factors for severe COVID: Current: * Age \> 65 years old * Physical inactivity (defined as \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07287137). StuddyBuddy aggregates publicly available trial information.